54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Esketamine
OTHER: Placebo
OTHER: Standard of Care

Sponsor

Janssen Research & Development, LLC